This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Vaxart (VXRT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Vaxart's (VXRT) second-quarter earnings call, investors are set to mainly focus on updates on the company's progress with oral vaccine candidates for COVID-19 and Norovirus.
Vaxart (VXRT) Enters an Agreement With Altesa for Antiviral
by Zacks Equity Research
Vaxart (VXRT) enters a licensing agreement with Altesa Biosciences, Inc., whereby the latter gets rights to develop, manufacture and commercialize vapendavir.
Implied Volatility Surging for Vaxart (VXRT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Vaxart (VXRT) stock based on the movements in the options market lately.
Do Options Traders Know Something About Vaxart (VXRT) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Vaxart (VXRT) stock based on the movements in the options market lately.
VAXART, INC. (VXRT) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
VAXART, INC. (VXRT) delivered earnings and revenue surprises of -40.00% and -17.99%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
VAXART, INC. (VXRT) Moves 5.6% Higher: Will This Strength Last?
by Zacks Equity Research
VAXART, INC. (VXRT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
VAXART, INC. (VXRT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, VAXART, INC. (VXRT) closed at $6.79, marking a -0.73% move from the previous day.
VAXART, INC. (VXRT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
VAXART, INC. (VXRT) closed the most recent trading day at $7.94, moving -1.85% from the previous trading session.
Hedge Fund Diaries: Who Was Buying Your Stocks?
by Kevin Cook
SEC 13Fs reveal trades from months ago, but also patterns of long-term bullish behavior.
Vaxart (VXRT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Vaxart's (VXRT) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its oral COVID-19 vaccine candidate, VXA-CoV2-1.
Biotech Bonanza: COVID Launches Science at Warp Speed
by Kevin Cook
From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.
Do Options Traders Know Something About Vaxart (VXRT) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Vaxart (VXRT) stock based on the movements in the options market lately.
Emergent (EBS) Posts Preliminary '20 Results, Gives 2021 View
by Zacks Equity Research
Emergent (EBS) tightens revenue view for 2020 and expects a consistent rise in sales of contract development and manufacturing services provided to other companies.
4 Small COVID-19 Vaccine Makers to Look Out for in 2021
by Kinjel Shah
Here we discuss four small biotech companies, NVAX, CVAC, VXRT and ARCT, that are making COVID-19 vaccine candidates, which may be approved in 2021, if successfully developed, and bring profits.
Do Options Traders Know Something About Vaxart (VXRT) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Vaxart (VXRT) stock based on the movements in the options market lately.
The Zacks Analyst Blog Highlights: INO, NVAX, TBIO and VXRT
by Zacks Equity Research
The Zacks Analyst Blog Highlights: INO, NVAX, TBIO and VXRT
4 Biotechs Likely to Gain on Coronavirus Vaccine Efforts
by Indrajit Bandyopadhyay
In the race to develop a coronavirus vaccine, Pfizer and its partner BioNTech have a lead, closely followed by Moderna. However, four other biotechs, NVAX, TBIO, INO and VXRT, still hold potential to gain from their vaccine development efforts.
Altimmune (ALT) Files IND for Phase I Study on Coronavirus Vaccine
by Zacks Equity Research
Altimmune (ALT) files a regulatory application to begin a phase I study in the United States on AdCOVID, its intranasal COVID-19 vaccine candidate. Stock rises.
Vaxart (VXRT) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
During Vaxart's (VXRT) impending third-quarter conference call, investors will keep tabs of its progress with its oral COVID-19 vaccine candidate VXA-CoV2-1.
Vaxart (VXRT) Begins Dosing in Oral Coronavirus Vaccine Study
by Zacks Equity Research
Vaxart (VXRT) doses the first subject in an early-stage study of its oral coronavirus vaccine candidate VXA-CoV2-1. Stock rises.
Biotech Stock Roundup: REGN, GILD's Coronavirus News & Other Pipeline Updates
by Zacks Equity Research
Regeneron (REGN) and Gilead (GILD) continue to be in the spotlight on coronavirus-related updates.
Kindred Shares Up on Expansion of Agreement With Vaxart
by Zacks Equity Research
Kindred (KIN) expands an agreement with Vaxart for the manufacturing of the latter's oral vaccine for COVID-19 and other vaccine candidates.
CureVac Begins Phase IIa Study on Coronavirus Vaccine Candidate
by Zacks Equity Research
CureVac (CVAC) doses the first patient in a phase IIa study on its COVID-19 vaccine candidate CVnCoV. Shares rise in after-hours trading following this development.
Do Options Traders Know Something About Vaxart (VXRT) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Vaxart (VXRT) stock based on the movements in the options market lately.
Vaxart (VXRT) Surges: Stock Moves 8.1% Higher
by Zacks Equity Research
Vaxart (VXRT) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.